22,99 €
inkl. MwSt.

Versandfertig in 6-10 Tagen
  • Broschiertes Buch

Although HIV-1 has been the most studied infectious agent in the last 30 years and Its widely believed that inducting of neutralizing antibodies were sufficient for the protection against HIV. A novel mode of action of HIV infection assumes that production of neutralizing anti-HIV antibodies is the main cause in enhancing the viral infection and its protection against destruction by the cytotoxic CD8+ T-cells. This postulation differs from the ordinary rationales that depend on the role of neutralizing antibodies in controlling the HIV infection. In this book we introduce ( V20E) as a new…mehr

Produktbeschreibung
Although HIV-1 has been the most studied infectious agent in the last 30 years and Its widely believed that inducting of neutralizing antibodies were sufficient for the protection against HIV. A novel mode of action of HIV infection assumes that production of neutralizing anti-HIV antibodies is the main cause in enhancing the viral infection and its protection against destruction by the cytotoxic CD8+ T-cells. This postulation differs from the ordinary rationales that depend on the role of neutralizing antibodies in controlling the HIV infection. In this book we introduce ( V20E) as a new therapeutic immune peptides modality with a highly promising cure for HIV-1 disease and human immunodeficiency syndrome.
Autorenporträt
Dr. Sherif Salah is a Consultant of immunology, vet.¿ Medicine Cairo University holds a Ph.D. degree in Immunology, Innovator of three Pharmaceuticals in Markets, published many articles and books in HIV, cancer and Multiple sclerosis and awarded four Patents of invention on novel ¿Biological molecules for Treatment of hepatitis C virus and HIV.¿